Abstract Purpose: To evaluate the application of apparent diffusion coefficient (ADC) values derived from diffusion-weighted imaging (DWI) using single-slice histogram analysis to
INTRODUCTION
Chemotherapy is the dominant treatment strategy for patients with advanced lung cancer.
Response Evaluation Criteria in Solid Tumors (RECIST) is often used as standard for evaluating treatment responses in lung cancer, which analyzes tumor size changes by employing computed tomography (CT) [1] . However, because of the relatively slow tumor shrinkage, the first response evaluation is often carried out after two cycles of chemotherapy by CT [2] , conventional imaging procedures may not accurately assess the response at the early treatment stage.
In recent years, investigations have reported that diffusion-weighted imaging (DWI) has potential for monitoring the early treatment response in many malignant tumors, including rectal cancer, cervical cancer, breast cancer, head and neck cancers, prostate cancer and brain tumors [3 -5] , and ADC derived from DWI changes as early as 24 h after therapy [6] . A variety of methods have been applied to measuring mean ADC values on ADC maps from various regions of interest (ROIs) located in the tumor [7, 8] . Histogram analysis based on the whole-tumor ROI method is preferred for differentiating or grading tumors or predicting treatment response in various organs [9] [10] [11] [12] . Single-slice histogram analysis can be used to generate the ADC histogram, which represents the pixel frequency of each ADC value for the slice image. Single-slice histogram analysis requires virtually no data manipulation and can be generated in seconds.
The goal of the present study is to analyze ADC values derived from DWI using single-slice histogram analysis, andalso to investigate the usefulness of ADC values in evaluating the response to chemotherapy in lung cancer.
EXPERIMENTAL Subjects
This study was approved by the Ethical Committee of Nanjing Drum Tower Hospital, Nanjing, China (approval no. EH201501-3), and was performed according to the guidelines of Declaration of Helsinki [13] . All patients were informed about the potential contraindications and benefits associated with DWI and contrastenhanced magnetic resonance imaging (MRI).
Patients in this study were diagnosed with stage IIIB or IV histologically confirmed advanced lung cancer at Nanjing Drum Tower Hospital (Nanjing, China) from Feb. 2015 to Aug. 2016 and met the following inclusion criteria: the largest diameter of the pulmonary mass was 3.0 cm or larger, no history of previous chemotherapy or radiation therapy, and no contraindication to high-field strength MRI (no claustrophobia and no known metallic implants). Lung cancer in all patients was pathologically confirmed by bronchoscopic biopsy or percutaneous lung biopsy. The histological types of cancer in patients included adenocarcinomas, small cell carcinoma and squamous cell carcinoma. The exclusion criteria included: having contraindication to gadopentetate dimeglumine (allergy or renal dysfunction), undergoing radiotherapy simultaneously with chemotherapy, interruption of treatment in 3 months, and poor visualization of the tumor by MRI. Tumor response after 3 months of therapy was evaluated according to the RECIST criteria 2 , including target and nontarget lesions at CT. Tumor response after therapy was classified as follows: responderswhen the target lesion disappeared or when the longest diameter of the target lesion decreased by at least 30 % from the pre-therapy size; and non-responders -when the target lesion was not classified as a responder or new lesions appeared [14] .
Image acquisition
Pre-treatment MRIs and post-treatment MRIs were obtained within 1 week prior to the first course of chemotherapy and 2 weeks after the start of the first course of chemotherapy, respectively. MRI was carried out by a 1.5-T unit with a body phased array coil (Avanto, Siemens, Germany). Firstly, breath-hold T2-weighted coronal images and T1-and T2-weighted axial images were obtained. Subsequently, breath-free DWI was obtained in the transverse plane using single-shot, spin-echo echo-planar imaging sequence with b values of 50 and 800 s/mm 2 . By using the indicated b values above, ADC maps were obtained from DWI. The total acquisition time for DWI was 50 s. After DWI, the contrastenhanced T1-weighted images were performed in the axial plane following administration of Gd-DTPA (Magnevist, Germany).
Data analysis
Generation and analysis of single-slice ADC histogram. A free-standing workstation (UNITED IMAGING Medical Systems) was used and single-slice ADC histograms were obtained by using the FuncTool of the workstation. The single axial slice was selected according to the level of the largest diameter of the tumor. Tumor boundaries were defined in reference to the T2-weighted and contrast-enhanced T1-weighted images. The ROIs were slightly smaller than actual tumor size to reduce the influence of partial volume effect. The peak ADC value (ADC peak ) and lowest ADC value (ADC lowest ) of the histograms were recorded. The peak value for each case was recorded as the ADC peak and the left leading edge of the histogram (where the voxel frequency was approximately 5 pixels) was recorded as the ADC lowest .
Statistical analysis
SPSS software version 13.0 (SPSS Inc., Chicago, IL, USA) was used for data analysis. Paired t-tests were used to compare differences between preand post-treatment MRI parameters in the same patient. Independent samples t-tests were performed to compare the differences between responders and nonresponders groups. p < 0.05 was considered as statistically significant.
RESULTS
Among 25 patients, the DWI of 22 (88 %) was graded as good or moderate. The DWI of the other three patients (12 %) was graded as poor and they were excluded from this study. All 22 patients with qualified baseline DWI received chemotherapy. Response assessment after 3 months of therapy was successfully performed. As a result, 13 and 9 patients were classified after therapy as responders and non-responders, respectively.
Single-slice ADC histograms were generated and ADC peak and ADC lowest were recorded from pretreatment and post-treatment ADC maps. Results and comparisons of ADC lowest and ADC peak are shown in Table 1 and Table 2 . No significant difference was observed in pretreatment ADC lowest and ADC peak between responders and non-responders (p = 0.855 and p = 0.606, respectively).
After chemotherapy, 13 responders had significant increases in ADC lowest and ADC peak compared with pre-treatment value (p < 0.001). Nine non-responders had a significant increase in ADC lowest (p < 0.05), while there was no significant increase in ADC peak (p > 0.05). Changes in ADC peak were more significant in the responder group than in the non-responder group (p = 0.024). Although no statistically changes in ADC lowest were larger in the responder group than that in non-responder group (p = 0.178).
DISCUSSION
Histogram analysis is usually used to analyze pixel numbers with the same signal intensity in an ROI, evaluate the distributions of tumor signal intensity, and describe the heterogeneity of the tumor. In particular, histogram analysis for the whole tumor can reduce the arbitrariness that can occur with drawing ROIs. Hence, ADC histogram analysis has been considered to be a more reproducible method to determine tumor heterogeneity, which is significant because heterogeneity is associated with poorer prognosis [15, 16] .
The tumor heterogeneity change can be analyzed intuitively by histogram and quantitatively by descriptive parameters of the histogram [17] . However, the major problem in ROI drawing for the whole lesion may be the irregular shape of lung cancer. Histogram analysis of the whole lung cancer lesionis laborintensive and requires professional software that is not commonly available in a clinic. The United Imaging FuncTool can rapidly analyze the singleslice ADC map to produce a histographic display of voxel occurrence frequency as a function of ADC value, e.g., ADC peak , ADC lowest and the overall shape of the ADC histogram [18] .
In this study, the changes in ADC peak were more significant in the responder group than in the non-responder group, which had been previously reported for other tumors [9] . ADC peak indicates that a larger proportion of the tumor, has the highest frequency, and tissues with high ADC values account for a significant part of the whole lesion. We speculated that if this part of the tumor greatly changed during the treatment, so would the value of the peak. Thus, ADC peak may be a promising parameter to assess early treatment responses in lung cancer.
The results demonstrated that ADC lowest of the tumor increased after treatment, both in the responder group and non-responder group, and that the changes in the responder group were larger, although not significant than in the nonresponder group. This result was not consistent with the results of previous research. Previous findings demonstrated that low percentile ADC values taken from the left leading edge of the tumor histogram increased more after treatment in the responder group than in the non-responder group [26] . We speculate that this was because the ADC lowest was not stable and the number of pixels of ADC lowest from the histogram was relatively small. Additionally, this value may be easily affected by noise, artifacts, and adjacent structures, which are difficult to avoid. In addition, some ROIs encompassed cavities found in the tumor or occurring after the biopsy, which would also affect the results (Figure 1 ).
Besides various ADC values, the shape of the ADC histogram also indicated the character of the tissue structure. In addition, by using histogram analysis in pre-and post-treatment, the histogram could show changes in tumor heterogeneity. The histogram of the responder group shifted obviously to the right side ( Figure  2) , indicating a larger proportion of tumors with a higher ADC value after treatment than prechemotherapy. However, the histogram graph did not shift significantly to the right side in the non-responder group (Figure 3) . In responder group, tumor cell necrosis resulted in increased ADC after therapy. This result is consistent with reports of other tumors in the literature [19, 20] . The findings suggest that single-slice ADC histogram analysis is a rapid and clinically useful technique to monitor the early tumor response and predict the effectiveness of lung cancer therapy.
The present study has some limitations. There were few patients were enrolled in this study. In future studies, the inclusion of more patients will help determine and validate the proper cutoff value for detecting responders in single-slice ADC histogram analysis. We used b values of 50 and 800 in the diffusion MRI protocol, but other b values were not used. Thus, the best b value for lung imaging was not determined. It will be necessary to use other b values for DWI to evaluate the effectiveness of the therapy. ; the number of pixels is displayed on the y-axis. The histogram graph shifts visibly to the right side after two weeks of therapy. After 3 months of therapy, the largest diameter of target lesions decreased by at least 90 % (E) 
CONCLUSION
ADC values obtained from single-slice histogram analysis of lung cancer may provide a useful tool for monitoring early tumor response and evaluating the effectiveness of a therapy. If this method is successfully used in practice, physicians would be able to reliably predict the early response to chemotherapy for lung cancer. Once the candidate drugs have been shown to be ineffective, patients could immediately try different anticancer drugs. This method will avoid situations where the toxic effects of anticancer drugs are tolerated without any corresponding clinical benefit.
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